➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Medtronic
Express Scripts
Dow
Colorcon

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XPOVIO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for XPOVIO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04349098 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-04-30 The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in patients with severe COVID-19 compared to placebo.
NCT04355676 Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-04-30 The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.
NCT04414475 A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2020-06-30 The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
NCT04421378 A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Recruiting Karyopharm Therapeutics Inc Phase 1/Phase 2 2020-06-01 This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 dose (RP2D), preliminary efficacy, and safety of selinexor in combination with SoC therapy for newly diagnosed glioblastoma multiforme (GBM) (nGBM) or recurrent GBM (rGBM). The study will independently evaluate 3 different combination regimens in 3 treatment arms in participants with nGBM O6-methylguanine-DNA-methyltransferase [MGMT] promotor unmethylated [uMGMT] disease in Arm A, MGMT methylated [mMGMT]) in Arm B, and participants with rGBM regardless of MGMT status in Arm C. The second phase of the study will compare selinexor+SoC treatments versus SoC treatment alone in the three treatment Arms.
NCT04640779 Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting National Cancer Institute (NCI) Phase 1 2020-12-15 This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with diffuse large B cell lymphoma or mantle cell lymphoma that has cancer cells remaining after attempts to remove the cancer have been made (residual), has come back (relapsed) or does not respond to treatment (refractory). Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma.
NCT04640779 Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Residual, Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting Mayo Clinic Phase 1 2020-12-15 This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with diffuse large B cell lymphoma or mantle cell lymphoma that has cancer cells remaining after attempts to remove the cancer have been made (residual), has come back (relapsed) or does not respond to treatment (refractory). Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for lymphoma.
NCT04717700 Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients Not yet recruiting Karyopharm Therapeutics Inc Phase 2 2021-04-01 An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for XPOVIO

Condition Name

Condition Name for XPOVIO
Intervention Trials
Coronavirus Infection 2
Multiple Myeloma 2
Recurrent Plasma Cell Myeloma 2
Refractory Plasma Cell Myeloma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for XPOVIO
Intervention Trials
Neoplasms, Plasma Cell 5
Multiple Myeloma 5
Severe Acute Respiratory Syndrome 2
Coronavirus Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for XPOVIO

Trials by Country

Trials by Country for XPOVIO
Location Trials
United States 11
Norway 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for XPOVIO
Location Trials
Minnesota 3
Colorado 1
Wisconsin 1
Pennsylvania 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for XPOVIO

Clinical Trial Phase

Clinical Trial Phase for XPOVIO
Clinical Trial Phase Trials
Phase 2 7
Phase 1/Phase 2 3
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for XPOVIO
Clinical Trial Phase Trials
Not yet recruiting 9
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XPOVIO

Sponsor Name

Sponsor Name for XPOVIO
Sponsor Trials
Karyopharm Therapeutics Inc 8
National Cancer Institute (NCI) 4
Mayo Clinic 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for XPOVIO
Sponsor Trials
Industry 9
Other 6
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Express Scripts
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.